Literature DB >> 17209083

Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole.

Simone Schuller1, Cecile Clercx.   

Abstract

Long-term outcomes (mean 38+/-17 months) were evaluated in 27 dogs with sinonasal aspergillosis after successful medical treatment using intranasal infusions of 1% or 2% enilconazole (1%, n=15; 2%, n=12). Long-term outcomes with both treatment protocols were good, with half of the dogs being asymptomatic throughout the follow-up period. The remaining dogs showed mild clinical signs compatible with chronic rhinitis/sinusitis. These clinical signs were interpreted as chronic lymphoplasmacytic rhinitis/sinusitis and episodes of bacterial rather than fungal infection. Three dogs had confirmed reinfection or relapse 2 to 36 months after clinical resolution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17209083     DOI: 10.5326/0430033

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  4 in total

1.  Sinonasal tumor in 3 dogs after successful topical treatment for frontal sinus aspergillosis.

Authors:  Valentina Greci; Damiano Stefanello; Mauro Di Giancamillo; Carlo M Mortellaro
Journal:  Can Vet J       Date:  2009-11       Impact factor: 1.008

2.  Sinonasal aspergillosis: Outcome after topical treatment in dogs with cribriform plate lysis.

Authors:  Beatriz Belda; Nicholas Petrovitch; Kyle G Mathews
Journal:  J Vet Intern Med       Date:  2018-06-29       Impact factor: 3.333

3.  Minimally invasive treatment of sino-nasal aspergillosis in dogs.

Authors:  Clara Ballber; Tracy L Hill; Nick X Bommer
Journal:  J Vet Intern Med       Date:  2018-10-16       Impact factor: 3.333

4.  Utility of fungal polymerase chain reaction on nasal swab samples in the diagnosis and monitoring of sinonasal aspergillosis in dogs.

Authors:  Tom Biénès; Emilie Vangrinsven; Aline Fastrès; Mutien-Marie Garigliany; Frédéric Billen; Cécile Clercx
Journal:  J Vet Intern Med       Date:  2022-06-16       Impact factor: 3.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.